At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
TAK-831 T2 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-Label, Randomized, Single Dose, 5-Period, 5-Treatment Study to Evaluate the Relative Bioavailability and Effect of Food on TAK-831 Tablet Formulations in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating TAK-831 T2 and TAK-831 T3 for Healthy Volunteers. Completed, enrolled 16 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the oral BA of TAK-831 T3 tablet formulation relative to TAK-831 T2 tablet formulation under fasting conditions and to assess the effect of food on the pharmacokinetics (PK) of TAK-831 T3 tablet formulation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
CollaboratorsTakeda
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartOct 2018
Primary CompletionDec 2018
Study CompletionDec 2018
TodayJul 2026
First PostedOct 16, 2018
Enrollment StartOct 18, 2018
Primary CompletionDec 11, 2018
Study CompletionDec 22, 2018
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 7.7 years ago
Interventions
TAK-831 T2drug
TAK-831 T2 Tablets.
TAK-831 T3drug
TAK-831 T3 Tablets.